Mongoose Bio Recognized as Top-10 Most Promising Biotech Companies
Houston, Texas, November 7, 2024 – Mongoose Bio, a private clinical-stage biopharmaceutical company pioneering next generation precision T-cell based therapies targeting solid cancers, today announced that it has been recognized as one of the top 10 most promising companies at the 13th Annual Texas Life Science Forum, which took place in Houston, Texas this week.
“This award is a testament to the groundbreaking work of our team at Mongoose Bio,” said Neil Warma, President and CEO of Mongoose Bio. “We are honored to be acknowledged among such innovative leaders in the life sciences sector. This award reinforces our commitment to advancing transformative cancer therapies that have the potential to significantly impact patients’ lives.”
Neil Warma presented an update of Mongoose Bio’s technology, IP and clinical development of its proprietary TCR-T therapies to investors and scientists.
“We are grateful to the judges in recognizing the potential of Mongoose Bio,” said Dr. Cassian Yee Founder of Mongoose Bio and Endowed Professor at MD Anderson Cancer Center. “This acknowledgment underscores the potential of our pioneering work in TCR-T cell therapy and our ability to potentially transform the treatment of cancer. Our mission is to advance these transformative treatments into the clinic and bring new hope to patients battling some of the most challenging cancers.”
About Mongoose Bio, Inc.
Mongoose Bio is a clinical-stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for solid cancers. Mongoose Bio combines a combination of proprietary methodologies including a Immunopeptidome Discovery Platform (IDP) and Epigenetic T Cell Reprogramming (ECMR) to develop next-generation adoptive TCR-T cell therapies. More information can be found at www.mongoosebio.com.
About Texas Life Science Forum
The Texas Life Science Forum, co-hosted by BioHouston and Rice Alliance, is the premier life science and healthtech event in Texas that brings together members from industry, emerging life science companies, academic institutions and investors. Presentations are given by innovative life science companies, and the forum provides the ability to network and enjoy exciting panels, keynotes and speakers.
Forward Looking Statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. These statements reflect the company’s current expectations regarding future events, including, but not limited to clinical development timelines, regulatory approvals, and commercial potential. Actual results could differ materially due to factors such as scientific, clinical, operational, or financial challenges. The company undertakes no obligation to update these statements except as required by law.
Investor Relation & Media Contact:
Email: info@mongoosebio.com